Maryland Caps What Public Health Plans Pay for Ozempic at $274: How State Drug Affordability Boards Work
Maryland's drug affordability board set payment limits on Ozempic and Jardiance for state and local government plans starting in 2027. Who is covered, why copays may not change, why Colorado's Enbrel limit is stuck in court, and what to ask your plan.
Key points
- Maryland's Prescription Drug Affordability Board voted to set upper payment limits on Ozempic ($274 per 30-day supply) and Jardiance ($6.80 per pill, or $204 per 30 days) for state and local government plans and purchasers, for drugs dispensed on or after January 1, 2027
- Both limits are pegged to Medicare's negotiated prices: $274 a month for semaglutide from 2027, and $197 a month for Jardiance in 2026, adjusted for inflation
- Board staff estimated savings of about $6.1 million compared with what Maryland governments pay after rebates, using 2024 claims; compared with list prices, the estimates were about $23 million for Ozempic and over $8 million for Jardiance
- The board's website says governments may apply the limits starting January 1, 2027 and must apply them after January 1, 2028; Medicaid, self-insured Medicare retiree plans (EGWPs), the AIDS Drug Assistance Program, and 340B purchases are excluded
- The Ozempic limit does not cover Wegovy or Rybelsus, and it limits what plans pay, not patient copays; people with coinsurance or deductibles are the most likely to see a change
- Colorado's first-in-the-nation UPL on Enbrel has been blocked by a preliminary injunction since July 1, 2026, on federal patent preemption grounds; the case is on appeal at the Federal Circuit
- As of August 2026, Avalere counted four states whose boards can set payment limits (Colorado, Maryland, Minnesota, Washington), and no limit had yet taken effect anywhere
Maryland sets a $274 limit on Ozempic for public plans
Maryland's Prescription Drug Affordability Board has voted to cap what state and local government health plans pay for two diabetes drugs, Ozempic (semaglutide) and Jardiance (empagliflozin), WYPR reported on November 17, 2026. The station called Maryland the first state to limit government health plan spending on the two drugs. The limits apply to payments for drugs dispensed or purchased on or after January 1, 2027.
The dollar amounts are in the board's proposed regulations, published in the Maryland Register on June 26, 2026. Ozempic's limit is $274 per 30-day supply. Jardiance's is $6.80 per pill, or $204 for 30 days. Board staff estimated that the two limits would cut state and local government spending by about $6.1 million, based on 2024 claims and compared with what those governments pay after rebates. On the same January date, Novo Nordisk plans to cut Ozempic's list price to $675 a month.
If you are a Maryland state, county, or city employee taking Ozempic, don't expect your copay to drop in January. The limit changes what your plan pays for the drug, and in 2027 your plan may not apply it at all.
What a drug affordability board does
A prescription drug affordability board (PDAB) is a state panel that studies whether specific drugs cost the state or its residents too much. Maryland created the first one in 2019, according to the Congressional Research Service.
Maryland's board picked Ozempic and Jardiance for cost reviews on May 20, 2024. In November 2025 it made a preliminary finding that Ozempic had created an "affordability challenge" for the state health care system. The finding it could discuss in public was about budget share: state and local governments' gross spending on Ozempic was more than 4.87% of their gross spending on all prescription drugs. For Jardiance, the share was above 1.8%, and the board also found that the drug's list price had risen much faster than inflation.
Boards can also recommend other fixes. Alongside the Ozempic limit, Maryland's board voted in May 2026 for a GLP-1 study, a bulk-purchasing or subscription model, a study of plan design and pharmacy benefit managers (PBMs, the companies that run drug benefits for health plans), and state participation in two federal payment models, BALANCE and GENEROUS.
Where the $274 comes from
An upper payment limit (UPL) is, in the Maryland board's words, "a maximum amount that eligible entities will reimburse for certain prescription drugs." It caps what a covered plan or government buyer pays. The drugmaker's list price stays where the company sets it. Vinny DeMarco, president of the Maryland Health Care for All coalition, put it this way to WYPR: "Now, the state is saying, you could charge whatever you want, but we are only going to pay a reasonable amount here in Maryland."
Maryland borrowed its number from Medicare. Under the 2022 Inflation Reduction Act, Medicare negotiates prices, called maximum fair prices (MFPs), for selected high-spending drugs in Part D, its pharmacy benefit. In November 2025, the Centers for Medicare & Medicaid Services (CMS) announced a price of $274 for a 30-day supply of semaglutide, sold as Ozempic, Rybelsus, and Wegovy, starting January 1, 2027. That is 71% below the 2024 list price of $959. In February 2026, Maryland's board told staff to build the Ozempic limit from that Medicare price, and the staff calculation lands on exactly $274.
Jardiance went through the same math. Its Medicare price for 2026 is $197 a month, down from a 2023 list price of $573. Staff rounded the per-pill price up to $6.60 ($198 a month) as a 2026 baseline, then added 2.7% for inflation to reach $6.80 a pill for 2027.
A few details in the rules matter for pharmacies and patients:
- Dispensing fees are extra. Staff concluded that Medicare lets pharmacies receive the negotiated price plus a dispensing fee, so the Maryland limit excludes that fee too.
- Annual inflation updates start in 2028. Each limit will rise with the consumer price index (CPI-U), the government's basic measure of inflation.
- Shortages pause the limit. If the FDA lists either drug as in shortage, its limit is suspended automatically until the shortage is resolved.
- Better deals are allowed. Plans and PBMs can still negotiate prices below the limit. The board's rules do not let it set a limit below Medicare's price.
Copay caps, Medicare prices, and payment limits compared
These three policies limit different payments.
| Policy | What it limits | Who it applies to | Example |
|---|---|---|---|
| Copay cap | What you pay at the pharmacy counter | People in the covered plans | Medicare's $35 monthly limit on covered insulin |
| Medicare negotiated price (MFP) | What Medicare drug plans pay for the drug | People in Medicare Part D plans | Semaglutide at $274 a month from 2027 |
| State upper payment limit | The most a covered payer or buyer will reimburse | In Maryland, state and local government plans and purchasers | Ozempic at $274 a month; Jardiance at $204 |
A copay cap lowers your bill directly. The other two change what the plan pays, and your share depends on your plan's cost-sharing rules. Our insulin cost guide covers copay caps in detail.
Medicare also has a second semaglutide price. Under a separate November 2025 agreement with the White House, Novo Nordisk committed to offer Medicare $245 for all forms of semaglutide, according to the Academy of Managed Care Pharmacy. Our TrumpRx guide covers that deal and what Medicare patients pay.
Who in Maryland is covered, and who is left out
The board's implementation rules, published as proposed regulations on June 12, 2026, define the "eligible governmental entities" that must follow a limit. They include:
- health plans that cover state employees, plus county, bicounty, and municipal employee plans
- state and county correctional facilities
- state hospitals
- health clinics at state colleges and universities
The same rules exclude Maryland Medicaid, the Maryland AIDS Drug Assistance Program, government retiree drug plans run as self-insured Medicare employer group waiver plans (EGWPs), and entities that buy at Medicaid prices or through the federal 340B discount program. Private employer plans, marketplace plans, and Medicare drug plans are outside the limit too. If you have Medicaid, our state-by-state Medicaid guide is the better reference.
The Ozempic limit names Ozempic's FDA application number, so it applies to Ozempic only. Wegovy and Rybelsus contain the same active ingredient but are not covered by Maryland's limit.
Timing is softer than the January 1 date suggests. The board's website says governments "will have the option to start implementing these UPLs starting on January 1, 2027, but they will be required to implement all active UPLs starting after January 1, 2028." Under the proposed rules, drug contracts signed or amended on or after January 1, 2028 must include a clause requiring contractors to follow Maryland's limits, and a government must comply once such a contract is in effect. A county whose pharmacy contract renews later could reach the limit later.
Why your copay probably won't change
The limit caps the total amount paid for a prescription. Board staff wrote that a limit's value includes the patient's out-of-pocket share, apart from dispensing fees. So whatever you pay is counted inside the $274, with any dispensing fee paid separately.
What that means for you depends on your plan design. A flat copay (a set dollar amount per fill) would not change because of the limit. If you pay coinsurance (a percentage of the drug's cost) or pay toward a deductible, a lower allowed amount could lower your share, depending on how the plan calculates it. Novo Nordisk made a similar argument for its own list-price cut, saying it was aimed at people "whose out-of-pocket costs are linked to list price."
WYPR reported that patients "will not be on the hook for the remaining costs" and that drug companies would absorb them in most scenarios. The board's economic impact statement says savings "may ultimately be realized through a decrease in revenue by the manufacturer," and that governments may use them to expand coverage.
The open question is the pharmacy. Drugmakers sell mostly to wholesalers at list price, and wholesalers sell to pharmacies, CRS noted in describing Amgen's sales. If a pharmacy pays more than $274 for an Ozempic pen and the plan reimburses only $274 plus a dispensing fee, the pharmacy loses money on each fill. Medicare has federal rules for this: board staff noted that under CMS guidance, the negotiated price is both the most a Part D plan pays and the most a pharmacy's net cost should be. State limits have no equivalent rulebook yet. As of August 2026, Avalere Health reported that no UPL had taken effect anywhere and no "effectuation guidance" had been published.
Some drugmakers and patient groups warned that pharmacies could stop stocking the drugs. Aimed Alliance, a health policy group, wrote to the board that limits "may have downstream consequences on patient access, including through changes in formulary coverage, utilization management, or other responses to reimbursement changes." The board said it would change the policy if access suffers. Its proposed reporting rules require each government to report the drug's formulary placement before and after a limit starts.
Colorado's Enbrel limit is on hold in federal court
Colorado's board set the country's first UPL in October 2025: $600 per 50 mg unit of Enbrel, Amgen's arthritis and psoriasis drug, close to Medicare's negotiated price, according to the Congressional Research Service. The Colorado Sun put that at about $31,000 per patient per year, against a wholesale cost of about $96,000. The limit was due to start January 1, 2027.
Amgen sued on October 30, 2025, arguing that federal patent law preempts the state limit. On July 1, 2026, Chief Judge Daniel Domenico of the U.S. District Court in Denver blocked the limit with a preliminary injunction, which stops enforcement while the case continues. "Since under binding Federal Circuit precedent, caps on the price of patented drugs like Enbrel are preempted by federal law, Amgen's motion must be granted," he wrote. Colorado had argued that distributors or pharmacies might absorb the cost. Domenico wrote that Amgen "will receive less money from its wholesalers" regardless.
The injunction is on appeal at the U.S. Court of Appeals for the Federal Circuit (Amgen Inc. v. Mizner, No. 26-2111). Avalere noted that Colorado, like Maryland, tied its number to Medicare's negotiated price, so the ruling raises doubts about whether that approach protects a state limit from patent challenges. Ozempic and Jardiance are both still sold only as brand-name drugs in the U.S. We did not find a reported lawsuit against Maryland's limits as of November 17, 2026.
Where else boards can set limits
Four states had boards with authority to set UPLs as of August 2026, according to Avalere: Colorado, Maryland, Minnesota, and Washington. Minnesota's law exempts Medicare and plans regulated by ERISA, the federal law that governs most employer health plans, CRS reported. Minnesota and Washington are earlier in the process than Maryland.
Other states have pulled back or stalled. Avalere reported that Oregon's board has reviewed more than 30 drugs and sends recommendations to its legislature but cannot set limits. New Hampshire and Ohio dissolved their boards in 2025 budget bills. Virginia's governor vetoed a bill tied to Medicare prices for the third straight session, and an Illinois UPL bill stalled in committee.
Maryland may go further. According to WYPR, putting these limits in place would let the board set limits on the same two drugs for private insurance in 2028, with savings that could reach more than $150 million a year. Gov. Wes Moore and several lawmakers have also signaled support for legislation that would let the board set limits on any drug with a Medicare negotiated price. There are 25 such drugs so far.
Questions to ask your plan before January
If you are a Maryland public employee or a retiree not yet on Medicare, call the number on your pharmacy benefit card and ask:
1. Will our plan apply the Ozempic and Jardiance limits in 2027, or wait until it is required in 2028?
2. Will Ozempic stay on the formulary at the same tier, with the same prior authorization rules?
3. Is my cost share a flat copay, coinsurance, or a deductible? Only the last two could move with the price your plan pays.
4. Which pharmacies will fill it? If a pharmacy says it can't fill your prescription at the new rate, ask the plan for an in-network pharmacy that can.
If you lose access or your costs rise, you can tell the board through its Report an Affordability Issue page. If you take Wegovy for weight loss instead, the Maryland limit does not apply, and our guide to losing employer GLP-1 coverage in 2027 may be more useful.
Updates and corrections
No corrections yet.
Limitations
- Dollar amounts come from the proposed regulations published in the Maryland Register on June 26, 2026; the final adopted text had not appeared in the Register as of the November 13, 2026 issue we checked
- The implementation and contracting rules (COMAR 14.01.06) cited here are the proposed version published June 12, 2026; the final version may differ
- Maryland Matters coverage of the board's final vote was not accessible to us; the description of the vote relies on WYPR and the board's own website
- The $6.1 million savings estimate assumes every eligible government applies the limits and that use of the drugs does not change; it leaves out correctional facilities, state hospitals, and college clinics, which are not in the claims database the board used
- The $150 million private-market figure is from WYPR's reporting and was not found in a board document we reviewed
- How a lower plan payment affects a specific patient's cost share depends on plan design; we did not review any Maryland state or county plan documents
Citations
- 1.
- 2. Upper Payment Limitsregulatory Maryland Prescription Drug Affordability Board 2026
- 3. Maryland Register, Volume 53, Issue 13 (June 26, 2026): Proposed COMAR 14.01.07.01 Upper Payment Limit for Jardiance and 14.01.07.02 Upper Payment Limit for Ozempicregulatory Maryland Division of State Documents 2026
- 4. Maryland Register, Volume 53, Issue 12 (June 12, 2026): Proposed COMAR 14.01.06 Implementation and Monitoring of Upper Payment Limitsregulatory Maryland Division of State Documents 2026
- 5. Board Selected Drugs: Ozempicregulatory Maryland Prescription Drug Affordability Board 2026
- 6. Board Selected Drugs: Jardianceregulatory Maryland Prescription Drug Affordability Board 2026
- 7. Ozempic: Calculations and Analyses Underpinning Potential Upper Payment Limit (UPL) Valuesregulatory Maryland Prescription Drug Affordability Board 2026
- 8. Jardiance: Calculations and Analyses Underpinning Potential Upper Payment Limit (UPL) Values, Version 2.0regulatory Maryland Prescription Drug Affordability Board 2026
- 9. Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027regulatory Centers for Medicare & Medicaid Services 2025
- 10. Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026regulatory Centers for Medicare & Medicaid Services 2024
- 11. CMS Delivers Savings for Seniors on 15 Major Drugs for Cancer and Chronic Diseasepress-release Centers for Medicare & Medicaid Services 2025
- 12. Federal Update: CMS Releases Negotiated Prices for 15 Drugs Under Medicare Drug Price Negotiation Programpolicy-analysis Academy of Managed Care Pharmacy 2025
- 13.
- 14. Litigation over State Attempts to Lower Drug Costs: Prescription Drug Affordability Boards (PDABs)policy-analysis Congressional Research Service (LSB11390) 2026
- 15. Judge temporarily blocks Colorado's first-in-the-nation price cap on a prescription drugnews The Colorado Sun 2026
- 16. Amgen Inc. v. Mizner, No. 26-2111 (Fed. Cir.): Plaintiffs' docketing statementlegal U.S. Court of Appeals for the Federal Circuit 2026
- 17. State pricing controls at an inflection point: Maximum Fair Price and the shifting Prescription Drug Affordability Board landscapepolicy-analysis Avalere Health 2026
- 18. The Changing Insulin Affordability Landscape: Lower Out-of-Pocket Costs and Expanded Access Pathwaysregulatory HHS Office of the Assistant Secretary for Planning and Evaluation 2026
Peptides in this article
Full peptide profiles with evidence levels, dosing data, and safety notes live on peptidelist.org.
Related insights
GLP-1 Drugs and Eating Disorders: Who May Benefit, Who Is at Risk, and the New Screening Advice
A 60-week Penn trial found semaglutide eased loss-of-control eating and body-image worries in adults with obesity, while a 45-member expert panel says people with active anorexia or restrictive bulimia should generally avoid these drugs. Semaglutide is not approved to treat binge-eating disorder.
Peptide Drugs for Alzheimer's After PRI-002's Phase 2 Miss and Semaglutide's EVOKE Failure
Priavoid's oral all-D-peptide missed its 48-week goal in a 304-person trial, with better numbers only in later, exploratory analyses. Novo Nordisk's 3,808-person semaglutide trials found no slowing at all. This guide explains both results, how their safety data relate to the approved antibodies, and how families can judge the next headline and find a trial.
Federal Employees and GLP-1s in 2027: Required Behavioral Therapy, Higher Costs, and How to Pay Less
Every FEHB and PSHB plan will require documented intensive behavioral therapy before and during weight-loss GLP-1 treatment in 2027, and many plans are raising member costs to 50%. A guide for federal employees, postal workers, and retirees before Open Season ends December 14.